centocor
said
friday
data
pivotal
trial
patients
crohn
disease
showed
treatment
ca2
monoclonal
antibody
produced
statistically
significant
positive
result
trial
primary
endpoint
closure
50
percent
open
fistulae.the
company
said
data
demonstrated
ca2
utility
treating
severe
complication
crohn
disease
patients
looking
forward
working
food
drug
administration
european
health
authorities
bringing
product
market
quickly
possible.the
company
said
results
study
released
appropriate
medical
forum
1997.centocor
biotechnology
company
primary
technological
focus
monoclonal
antibodies
dna
based
products
